$ZYME
Zymeworks Inc. Stock $zyme

$zyme Overview Financials Valuation SEC Filings Company Website

2023 Q1 Form 10-K Financial Statement

#000193765323000011 Filed on March 07, 2023

Income Statement

Concept	2023 Q1	2022 Q4	2022
Revenue	$35.58M	$402.5M	$412.5M
YoY Change	1756.89%	1925.63%	1446.03%
Cost Of Revenue
YoY Change
Gross Profit
YoY Change
Gross Profit Margin
Selling, General & Admin	$16.95M	$30.13M	$73.36M
YoY Change	40.15%	414.71%	72.36%
% of Gross Profit
Research & Development	$45.91M	$52.97M	$208.6M
YoY Change	-26.55%	-3.46%	4.43%
% of Gross Profit
Depreciation & Amortization	$1.584M	$1.681M	$6.220M
YoY Change	-35.77%	68.94%	-4.78%
% of Gross Profit
Operating Expenses	$45.91M	$83.10M	$208.6M
YoY Change	-38.46%	36.86%	-13.91%
Operating Profit	-$27.28M		$130.5M
YoY Change	-62.47%		-160.53%
Interest Expense	$4.805M	$1.068M	$3.596M
YoY Change	-8108.33%	253.64%	13.94%
% of Operating Profit			2.75%
Other Income/Expense, Net	-$487.0K	-$27.00K	$1.110M
YoY Change	-1136.17%	-212.5%	840.68%
Pretax Income	-$22.96M	$320.4M	$135.2M
YoY Change	-68.41%	-890.75%	-163.68%
Income Tax	$1.390M	$11.01M	$10.89M
% Of Pretax Income		3.43%	8.05%
Net Earnings	-$24.35M	$309.4M	$124.3M
YoY Change	-66.47%	-890.33%	-158.69%
Net Earnings / Revenue	-68.45%	76.88%	30.14%
Basic Earnings Per Share	-$0.36		$1.91
Diluted Earnings Per Share	-$0.37	$4.64	$1.90
COMMON SHARES
Basic Shares Outstanding	64.04M shares	63.00M shares	65.19M shares
Diluted Shares Outstanding	66.74M shares		65.25M shares

Balance Sheet

Concept	2023 Q1	2022 Q4	2022
SHORT-TERM ASSETS
Cash & Short-Term Investments	$340.8M	$492.2M	$492.2M
YoY Change	13.4%	94.86%	94.86%
Cash & Equivalents	$181.6M	$400.9M	$400.9M
Short-Term Investments	$159.2M	$91.32M	$91.32M
Other Short-Term Assets	$18.67M	$19.07M	$19.07M
YoY Change	-3.09%	-4.62%	-4.62%
Inventory
Prepaid Expenses
Receivables	$66.92M	$33.40M	$33.40M
Other Receivables	$0.00	$0.00	$0.00
Total Short-Term Assets	$426.4M	$544.7M	$544.7M
YoY Change	31.59%	88.99%	88.99%
LONG-TERM ASSETS
Property, Plant & Equipment	$23.51M	$24.71M	$47.65M
YoY Change	-52.69%	-50.35%	-4.26%
Goodwill	$12.02M	$12.02M
YoY Change		0.0%
Intangibles
YoY Change
Long-Term Investments	$72.47M	$886.0K	$886.0K
YoY Change	8079.91%	0.0%	0.0%
Other Assets	$18.36M	$17.08M	$17.08M
YoY Change	-12.64%	1.85%	1.85%
Total Long-Term Assets	$174.4M	$104.0M	$104.0M
YoY Change	64.57%	3.08%	3.08%
TOTAL ASSETS
Total Short-Term Assets	$426.4M	$544.7M	$544.7M
Total Long-Term Assets	$174.4M	$104.0M	$104.0M
Total Assets	$600.7M	$648.7M	$648.7M
YoY Change	39.72%	66.71%	66.71%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable	$6.433M	$7.863M	$7.863M
YoY Change	-54.14%	51.97%	51.97%
Accrued Expenses	$54.40M	$81.09M	$81.09M
YoY Change	-10.71%	43.06%	43.06%
Deferred Revenue	$2.353M	$2.353M
YoY Change
Short-Term Debt	$0.00	$0.00	$0.00
YoY Change
Long-Term Debt Due
YoY Change
Total Short-Term Liabilities	$67.32M	$95.63M	$95.63M
YoY Change	-15.82%	33.08%	33.08%
LONG-TERM LIABILITIES
Long-Term Debt	$121.0K	$124.0K	$124.0K
YoY Change	31.52%	24.0%	24.0%
Other Long-Term Liabilities	$3.595M	$3.101M	$58.23M
YoY Change	-94.55%	-95.34%	-12.45%
Total Long-Term Liabilities	$3.595M	$3.101M	$58.36M
YoY Change	-94.56%	-95.34%	-12.39%
TOTAL LIABILITIES
Total Short-Term Liabilities	$67.32M	$95.63M	$95.63M
Total Long-Term Liabilities	$3.595M	$3.101M	$58.36M
Total Liabilities	$127.2M	$155.8M	$155.8M
YoY Change	-13.78%	11.23%	11.23%
SHAREHOLDERS EQUITY
Retained Earnings	-$583.1M	-$558.8M
YoY Change		-18.2%
Common Stock	$1.053B	$1.038B
YoY Change		10.55%
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity	$473.5M	$493.0M	$493.0M
YoY Change
Total Liabilities & Shareholders Equity	$600.7M	$648.7M	$648.7M
YoY Change	39.72%	66.71%	66.71%

Cashflow Statement

Concept	2023 Q1	2022 Q4	2022
OPERATING ACTIVITIES
Net Income	-$24.35M	$309.4M	$124.3M
YoY Change	-66.47%	-890.33%	-158.69%
Depreciation, Depletion And Amortization	$1.584M	$1.681M	$6.220M
YoY Change	-35.77%	68.94%	-4.78%
Cash From Operating Activities	-$83.19M	$327.4M	$144.1M
YoY Change	50.13%	-748.12%	-174.88%
INVESTING ACTIVITIES
Capital Expenditures	$386.0K	$883.0K	$8.150M
YoY Change	-91.79%	-84.3%	-38.65%
Acquisitions
YoY Change
Other Investing Activities	-$137.8M	-$21.18M	-$40.72M
YoY Change	-645.28%	-662.3%	-125.79%
Cash From Investing Activities	-$138.2M	-$22.06M	-$53.85M
YoY Change	-771.83%	1088.21%	-137.24%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net			$107.5M
YoY Change			1165.4%
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities	$1.738M	-377.0K	$108.6M
YoY Change	-98.4%	-154.72%	1255.41%
NET CHANGE
Cash From Operating Activities	-$83.19M	327.4M	$144.1M
Cash From Investing Activities	-$138.2M	-22.06M	-$53.85M
Cash From Financing Activities	$1.738M	-377.0K	$108.6M
Net Change In Cash	-$219.3M	304.9M	$199.0M
YoY Change	-397.31%	-690.05%	-599.56%
FREE CASH FLOW
Cash From Operating Activities	-$83.19M	$327.4M	$144.1M
Capital Expenditures	$386.0K	$883.0K	$8.150M
Free Cash Flow	-$83.58M	$326.5M	$136.0M
YoY Change	39.03%	-681.61%	-166.08%

Facts In Submission

Frame	Concept Type	Concept / XBRL Key	Value	Unit
CY2022	dei	Amendment Flag AmendmentFlag	false
CY2022	dei	Document Fiscal Year Focus DocumentFiscalYearFocus	2022
CY2022	dei	Document Fiscal Period Focus DocumentFiscalPeriodFocus	FY
CY2022	dei	Entity Central Index Key EntityCentralIndexKey	0001937653
CY2022Q2	us-gaap	Class Of Warrant Or Right Number Of Securities Called By Each Warrant Or Right ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight	0.001	shares
CY2022	dei	Entity Well Known Seasoned Issuer EntityWellKnownSeasonedIssuer	No
CY2022Q4	us-gaap	Finance Lease Liability Noncurrent Statement Of Financial Position Extensible List FinanceLeaseLiabilityNoncurrentStatementOfFinancialPositionExtensibleList	http://fasb.org/us-gaap/2022#OtherLiabilitiesNoncurrent
CY2021Q4	us-gaap	Finance Lease Liability Noncurrent Statement Of Financial Position Extensible List FinanceLeaseLiabilityNoncurrentStatementOfFinancialPositionExtensibleList	http://fasb.org/us-gaap/2022#OtherLiabilitiesNoncurrent
CY2021Q4	us-gaap	Finance Lease Liability Statement Of Financial Position Extensible List FinanceLeaseLiabilityStatementOfFinancialPositionExtensibleList	http://fasb.org/us-gaap/2022#AccountsPayableAndAccruedLiabilitiesCurrentAndNoncurrent
CY2022Q4	us-gaap	Finance Lease Liability Statement Of Financial Position Extensible List FinanceLeaseLiabilityStatementOfFinancialPositionExtensibleList	http://fasb.org/us-gaap/2022#AccountsPayableAndAccruedLiabilitiesCurrentAndNoncurrent
CY2022	dei	Document Type DocumentType	10-K
CY2022	dei	Document Annual Report DocumentAnnualReport	true
CY2022	dei	Document Period End Date DocumentPeriodEndDate	2022-12-31
CY2022	dei	Current Fiscal Year End Date CurrentFiscalYearEndDate	--12-31
CY2022	dei	Document Transition Report DocumentTransitionReport	false
CY2022	dei	Entity File Number EntityFileNumber	001-41535
CY2022	dei	Entity Registrant Name EntityRegistrantName	ZYMEWORKS INC.
CY2022	dei	Entity Incorporation State Country Code EntityIncorporationStateCountryCode	DE
CY2022	dei	Entity Tax Identification Number EntityTaxIdentificationNumber	88-3099146
CY2022	dei	Entity Address Address Line2 EntityAddressAddressLine2	108 Patriot Drive
CY2022	dei	Entity Address Address Line1 EntityAddressAddressLine1	Suite A
CY2022	dei	Entity Address City Or Town EntityAddressCityOrTown	Middletown
CY2022	dei	Entity Address State Or Province EntityAddressStateOrProvince	DE
CY2022	dei	Entity Address Postal Zip Code EntityAddressPostalZipCode	19709
CY2022	dei	City Area Code CityAreaCode	302
CY2022	dei	Local Phone Number LocalPhoneNumber	274-8744
CY2022	dei	Entity Voluntary Filers EntityVoluntaryFilers	No
CY2022	dei	Entity Current Reporting Status EntityCurrentReportingStatus	Yes
CY2022	dei	Entity Interactive Data Current EntityInteractiveDataCurrent	Yes
CY2022	dei	Entity Filer Category EntityFilerCategory	Non-accelerated Filer
CY2022	dei	Entity Small Business EntitySmallBusiness	true
CY2022	dei	Entity Emerging Growth Company EntityEmergingGrowthCompany	false
CY2022	dei	Icfr Auditor Attestation Flag IcfrAuditorAttestationFlag	false
CY2022	dei	Entity Shell Company EntityShellCompany	false
CY2022Q2	dei	Entity Public Float EntityPublicFloat	306000000	usd
CY2023Q1	dei	Entity Common Stock Shares Outstanding EntityCommonStockSharesOutstanding	64041287	shares
CY2022	dei	Auditor Firm AuditorFirmId	85
CY2022	dei	Auditor Name AuditorName	KPMG LLP
CY2022	dei	Auditor Location AuditorLocation	Vancouver, Canada
CY2022Q4	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	400912000	usd
CY2021Q4	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	201867000	usd
CY2022Q4	us-gaap	Short Term Investments ShortTermInvestments	91320000	usd
CY2021Q4	us-gaap	Short Term Investments ShortTermInvestments	50741000	usd
CY2022Q4	us-gaap	Accounts Receivable Net Current AccountsReceivableNetCurrent	33400000	usd
CY2021Q4	us-gaap	Accounts Receivable Net Current AccountsReceivableNetCurrent	15614000	usd
CY2022Q4	us-gaap	Prepaid Expense And Other Assets Current PrepaidExpenseAndOtherAssetsCurrent	19074000	usd
CY2021Q4	us-gaap	Prepaid Expense And Other Assets Current PrepaidExpenseAndOtherAssetsCurrent	19998000	usd
CY2022Q4	us-gaap	Assets Current AssetsCurrent	544706000	usd
CY2021Q4	us-gaap	Assets Current AssetsCurrent	288220000	usd
CY2022Q4	zyme	Deferred Financing Fee DeferredFinancingFee	10000	usd
CY2021Q4	zyme	Deferred Financing Fee DeferredFinancingFee	1214000	usd
CY2022Q4	us-gaap	Long Term Investments LongTermInvestments	886000	usd
CY2021Q4	us-gaap	Long Term Investments LongTermInvestments	886000	usd
CY2022Q4	us-gaap	Prepaid Expense Noncurrent PrepaidExpenseNoncurrent	15729000	usd
CY2021Q4	us-gaap	Prepaid Expense Noncurrent PrepaidExpenseNoncurrent	12490000	usd
CY2022Q4	us-gaap	Deferred Income Tax Assets Net DeferredIncomeTaxAssetsNet	1345000	usd
CY2021Q4	us-gaap	Deferred Income Tax Assets Net DeferredIncomeTaxAssetsNet	3070000	usd
CY2022Q4	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	24713000	usd
CY2021Q4	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	22783000	usd
CY2022Q4	us-gaap	Operating Lease Right Of Use Asset OperatingLeaseRightOfUseAsset	22937000	usd
CY2021Q4	us-gaap	Operating Lease Right Of Use Asset OperatingLeaseRightOfUseAsset	26987000	usd
CY2022Q4	us-gaap	Finite Lived Intangible Assets Net FiniteLivedIntangibleAssetsNet	8755000	usd
CY2021Q4	us-gaap	Finite Lived Intangible Assets Net FiniteLivedIntangibleAssetsNet	3838000	usd
CY2022Q4	us-gaap	Indefinite Lived Intangible Assets Excluding Goodwill IndefiniteLivedIntangibleAssetsExcludingGoodwill	17628000	usd
CY2021Q4	us-gaap	Indefinite Lived Intangible Assets Excluding Goodwill IndefiniteLivedIntangibleAssetsExcludingGoodwill	17628000	usd
CY2022Q4	us-gaap	Goodwill Goodwill	12016000	usd
CY2021Q4	us-gaap	Goodwill Goodwill	12016000	usd
CY2022Q4	us-gaap	Assets Assets	648725000	usd
CY2021Q4	us-gaap	Assets Assets	389132000	usd
CY2022Q4	us-gaap	Accounts Payable And Accrued Liabilities Current AccountsPayableAndAccruedLiabilitiesCurrent	87468000	usd
CY2021Q4	us-gaap	Accounts Payable And Accrued Liabilities Current AccountsPayableAndAccruedLiabilitiesCurrent	62789000	usd
CY2022Q4	us-gaap	Accrued Income Taxes Current AccruedIncomeTaxesCurrent	840000	usd
CY2021Q4	us-gaap	Accrued Income Taxes Current AccruedIncomeTaxesCurrent	0	usd
CY2022Q4	us-gaap	Derivative Fair Value Of Derivative Liability DerivativeFairValueOfDerivativeLiability	1642000	usd
CY2021Q4	us-gaap	Derivative Fair Value Of Derivative Liability DerivativeFairValueOfDerivativeLiability	7754000	usd
CY2022Q4	us-gaap	Operating Lease Liability Current OperatingLeaseLiabilityCurrent	3322000	usd
CY2021Q4	us-gaap	Operating Lease Liability Current OperatingLeaseLiabilityCurrent	1310000	usd
CY2022Q4	us-gaap	Contract With Customer Liability Current ContractWithCustomerLiabilityCurrent	2353000	usd
CY2021Q4	us-gaap	Contract With Customer Liability Current ContractWithCustomerLiabilityCurrent	0	usd
CY2022Q4	us-gaap	Liabilities Current LiabilitiesCurrent	95625000	usd
CY2021Q4	us-gaap	Liabilities Current LiabilitiesCurrent	71853000	usd
CY2022Q4	us-gaap	Operating Lease Liability Noncurrent OperatingLeaseLiabilityNoncurrent	24667000	usd
CY2021Q4	us-gaap	Operating Lease Liability Noncurrent OperatingLeaseLiabilityNoncurrent	30923000	usd
CY2022Q4	us-gaap	Contract With Customer Liability Noncurrent ContractWithCustomerLiabilityNoncurrent	30588000	usd
CY2021Q4	us-gaap	Contract With Customer Liability Noncurrent ContractWithCustomerLiabilityNoncurrent	32941000	usd
CY2022Q4	us-gaap	Other Liabilities Noncurrent OtherLiabilitiesNoncurrent	3101000	usd
CY2021Q4	us-gaap	Other Liabilities Noncurrent OtherLiabilitiesNoncurrent	2748000	usd
CY2022Q4	us-gaap	Deferred Income Tax Liabilities Net DeferredIncomeTaxLiabilitiesNet	1788000	usd
CY2021Q4	us-gaap	Deferred Income Tax Liabilities Net DeferredIncomeTaxLiabilitiesNet	1573000	usd
CY2022Q4	us-gaap	Liabilities Liabilities	155769000	usd
CY2021Q4	us-gaap	Liabilities Liabilities	140038000	usd
CY2021Q4	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.00001
CY2022Q4	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.00001
CY2022Q4	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	900000000	shares
CY2021Q4	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	900000000	shares
CY2022Q4	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	63059501	shares
CY2022Q4	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	63059501	shares
CY2021Q4	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	46633935	shares
CY2021Q4	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	46633935	shares
CY2022Q4	us-gaap	Common Stock Value CommonStockValue	886322000	usd
CY2021Q4	us-gaap	Common Stock Value CommonStockValue	741147000	usd
CY2022Q4	us-gaap	Preferred Stock Par Or Stated Value Per Share PreferredStockParOrStatedValuePerShare	0.00001
CY2021Q4	us-gaap	Preferred Stock Par Or Stated Value Per Share PreferredStockParOrStatedValuePerShare	0.00001
CY2021Q4	us-gaap	Additional Paid In Capital Common Stock AdditionalPaidInCapitalCommonStock	197710000	usd
CY2021Q4	us-gaap	Preferred Stock Shares Authorized PreferredStockSharesAuthorized	100000000	shares
CY2022Q4	us-gaap	Preferred Stock Shares Authorized PreferredStockSharesAuthorized	100000000	shares
CY2022Q4	us-gaap	Preferred Stock Shares Outstanding PreferredStockSharesOutstanding	1	shares
CY2022Q4	us-gaap	Preferred Stock Shares Issued PreferredStockSharesIssued	1	shares
CY2021Q4	us-gaap	Preferred Stock Shares Issued PreferredStockSharesIssued	0	shares
CY2021Q4	us-gaap	Preferred Stock Shares Outstanding PreferredStockSharesOutstanding	0	shares
CY2022Q4	us-gaap	Preferred Stock Value PreferredStockValue	0	usd
CY2021Q4	us-gaap	Preferred Stock Value PreferredStockValue	0	usd
CY2022Q4	zyme	Exchangeable Shares Issued ExchangeableSharesIssued	1424533	shares
CY2022Q4	zyme	Exchangeable Shares Outstanding ExchangeableSharesOutstanding	1424533	shares
CY2021Q4	zyme	Exchangeable Shares Issued ExchangeableSharesIssued	0	shares
CY2021Q4	zyme	Exchangeable Shares Outstanding ExchangeableSharesOutstanding	0	shares
CY2022Q4	zyme	Exchangeable Shares Value Issued ExchangeableSharesValueIssued	20442000	usd
CY2021Q4	zyme	Exchangeable Shares Value Issued ExchangeableSharesValueIssued	0	usd
CY2022Q4	us-gaap	Additional Paid In Capital Common Stock AdditionalPaidInCapitalCommonStock	151614000	usd
CY2022Q4	us-gaap	Accumulated Other Comprehensive Income Loss Net Of Tax AccumulatedOtherComprehensiveIncomeLossNetOfTax	-6659000	usd
CY2021Q4	us-gaap	Accumulated Other Comprehensive Income Loss Net Of Tax AccumulatedOtherComprehensiveIncomeLossNetOfTax	-6659000	usd
CY2022Q4	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-558763000	usd
CY2021Q4	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-683104000	usd
CY2022Q4	us-gaap	Stockholders Equity StockholdersEquity	492956000	usd
CY2021Q4	us-gaap	Stockholders Equity StockholdersEquity	249094000	usd
CY2022Q4	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	648725000	usd
CY2021Q4	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	389132000	usd
CY2022Q4	us-gaap	Commitments And Contingencies CommitmentsAndContingencies		usd
CY2021Q4	us-gaap	Commitments And Contingencies CommitmentsAndContingencies		usd
CY2022	us-gaap	Revenue From Contract With Customer Excluding Assessed Tax RevenueFromContractWithCustomerExcludingAssessedTax	412482000	usd
CY2021	us-gaap	Revenue From Contract With Customer Excluding Assessed Tax RevenueFromContractWithCustomerExcludingAssessedTax	26680000	usd
CY2020	us-gaap	Revenue From Contract With Customer Excluding Assessed Tax RevenueFromContractWithCustomerExcludingAssessedTax	38951000	usd
CY2022	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	208596000	usd
CY2021	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	199752000	usd
CY2020	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	171203000	usd
CY2022	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	73358000	usd
CY2021	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	42561000	usd
CY2020	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	55216000	usd
CY2022	us-gaap	Costs And Expenses CostsAndExpenses	281954000	usd
CY2021	us-gaap	Costs And Expenses CostsAndExpenses	242313000	usd
CY2020	us-gaap	Costs And Expenses CostsAndExpenses	226419000	usd
CY2022	us-gaap	Operating Income Loss OperatingIncomeLoss	130528000	usd
CY2021	us-gaap	Operating Income Loss OperatingIncomeLoss	-215633000	usd
CY2020	us-gaap	Operating Income Loss OperatingIncomeLoss	-187468000	usd
CY2022	us-gaap	Interest Income Expense Nonoperating Net InterestIncomeExpenseNonoperatingNet	3596000	usd
CY2021	us-gaap	Interest Income Expense Nonoperating Net InterestIncomeExpenseNonoperatingNet	1965000	usd
CY2020	us-gaap	Interest Income Expense Nonoperating Net InterestIncomeExpenseNonoperatingNet	5697000	usd
CY2022	us-gaap	Nonoperating Income Expense NonoperatingIncomeExpense	1110000	usd
CY2021	us-gaap	Nonoperating Income Expense NonoperatingIncomeExpense	1309000	usd
CY2020	us-gaap	Nonoperating Income Expense NonoperatingIncomeExpense	1648000	usd
CY2022	us-gaap	Other Operating Income Expense Net OtherOperatingIncomeExpenseNet	4706000	usd
CY2021	us-gaap	Other Operating Income Expense Net OtherOperatingIncomeExpenseNet	3274000	usd
CY2020	us-gaap	Other Operating Income Expense Net OtherOperatingIncomeExpenseNet	7345000	usd
CY2022	us-gaap	Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest	135234000	usd
CY2021	us-gaap	Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest	-212359000	usd
CY2020	us-gaap	Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest	-180123000	usd
CY2022	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	10893000	usd
CY2021	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	-516000	usd
CY2020	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	429000	usd
CY2022	us-gaap	Net Income Loss NetIncomeLoss	124341000	usd
CY2022	us-gaap	Comprehensive Income Net Of Tax ComprehensiveIncomeNetOfTax	124341000	usd
CY2021	us-gaap	Net Income Loss NetIncomeLoss	-211843000	usd
CY2021	us-gaap	Comprehensive Income Net Of Tax ComprehensiveIncomeNetOfTax	-211843000	usd
CY2020	us-gaap	Net Income Loss NetIncomeLoss	-180552000	usd
CY2020	us-gaap	Comprehensive Income Net Of Tax ComprehensiveIncomeNetOfTax	-180552000	usd
CY2022	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	1.91
CY2021	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-4.11
CY2020	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-3.58
CY2022	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	1.90
CY2021	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-4.61
CY2020	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-3.58
CY2022	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	65194775	shares
CY2021	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	51553869	shares
CY2020	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	50382497	shares
CY2022	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	65249184	shares
CY2021	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	52131596	shares
CY2020	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	50382497	shares
CY2019Q4	us-gaap	Stockholders Equity StockholdersEquity	245681000	usd
CY2020	us-gaap	Stock Issued During Period Value Stock Options Exercised StockIssuedDuringPeriodValueStockOptionsExercised	15430000	usd
CY2020	us-gaap	Stock Issued During Period Value Employee Stock Purchase Plan StockIssuedDuringPeriodValueEmployeeStockPurchasePlan	1618000	usd
CY2020	zyme	Adjustments To Additional Paid In Capital Fair Value Adjustment Reclassification Of Stock Options To Liabilities AdjustmentsToAdditionalPaidInCapitalFairValueAdjustmentReclassificationOfStockOptionsToLiabilities	110000	usd
CY2020	us-gaap	Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue	26945000	usd
CY2020	us-gaap	Stock Issued During Period Value New Issues StockIssuedDuringPeriodValueNewIssues	300910000	usd
CY2020	us-gaap	Net Income Loss NetIncomeLoss	-180552000	usd
CY2020Q4	us-gaap	Stockholders Equity StockholdersEquity	409922000	usd
CY2021	us-gaap	Stock Issued During Period Value Stock Options Exercised StockIssuedDuringPeriodValueStockOptionsExercised	9660000	usd
CY2021	us-gaap	Stock Issued During Period Value Employee Stock Purchase Plan StockIssuedDuringPeriodValueEmployeeStockPurchasePlan	3080000	usd
CY2021	us-gaap	Stock Issued During Period Value Restricted Stock Award Net Of Forfeitures StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures	0	usd
CY2021	us-gaap	Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue	38275000	usd
CY2021	us-gaap	Net Income Loss NetIncomeLoss	-211843000	usd
CY2021Q4	us-gaap	Stockholders Equity StockholdersEquity	249094000	usd
CY2022	us-gaap	Stock Issued During Period Value Stock Options Exercised StockIssuedDuringPeriodValueStockOptionsExercised	280000	usd
CY2022	us-gaap	Stock Issued During Period Value Employee Stock Purchase Plan StockIssuedDuringPeriodValueEmployeeStockPurchasePlan	2191000	usd
CY2022	us-gaap	Stock Issued During Period Value Restricted Stock Award Net Of Forfeitures StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures	0	usd
CY2022	us-gaap	Stock Issued During Period Value Conversion Of Convertible Securities StockIssuedDuringPeriodValueConversionOfConvertibleSecurities	0	usd
CY2022	zyme	Stock Issued During Period Value Exchange Of Shares Per The Redomiciliation StockIssuedDuringPeriodValueExchangeOfSharesPerTheRedomiciliation	0	usd
CY2022	us-gaap	Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue	9516000	usd
CY2022	us-gaap	Stock Issued During Period Value New Issues StockIssuedDuringPeriodValueNewIssues	107534000	usd
CY2022	us-gaap	Net Income Loss NetIncomeLoss	124341000	usd
CY2022Q4	us-gaap	Stockholders Equity StockholdersEquity	492956000	usd
CY2022	us-gaap	Profit Loss ProfitLoss	124341000	usd
CY2021	us-gaap	Profit Loss ProfitLoss	-211843000	usd
CY2020	us-gaap	Profit Loss ProfitLoss	-180552000	usd
CY2022	us-gaap	Depreciation Depreciation	6220000	usd
CY2021	us-gaap	Depreciation Depreciation	3739000	usd
CY2020	us-gaap	Depreciation Depreciation	3355000	usd
CY2022	us-gaap	Amortization Of Intangible Assets AmortizationOfIntangibleAssets	1015000	usd
CY2021	us-gaap	Amortization Of Intangible Assets AmortizationOfIntangibleAssets	2793000	usd
CY2020	us-gaap	Amortization Of Intangible Assets AmortizationOfIntangibleAssets	4160000	usd
CY2022	us-gaap	Share Based Compensation ShareBasedCompensation	4015000	usd
CY2021	us-gaap	Share Based Compensation ShareBasedCompensation	10756000	usd
CY2020	us-gaap	Share Based Compensation ShareBasedCompensation	29116000	usd
CY2022	us-gaap	Operating Lease Right Of Use Asset Amortization Expense OperatingLeaseRightOfUseAssetAmortizationExpense	4769000	usd
CY2021	us-gaap	Operating Lease Right Of Use Asset Amortization Expense OperatingLeaseRightOfUseAssetAmortizationExpense	3051000	usd
CY2020	us-gaap	Operating Lease Right Of Use Asset Amortization Expense OperatingLeaseRightOfUseAssetAmortizationExpense	2764000	usd
CY2022	us-gaap	Increase Decrease In Deferred Income Taxes IncreaseDecreaseInDeferredIncomeTaxes	-1940000	usd
CY2021	us-gaap	Increase Decrease In Deferred Income Taxes IncreaseDecreaseInDeferredIncomeTaxes	953000	usd
CY2020	us-gaap	Increase Decrease In Deferred Income Taxes IncreaseDecreaseInDeferredIncomeTaxes	-266000	usd
CY2022	zyme	Licensing Agreement Noncash Consideration LicensingAgreementNoncashConsideration	0	usd
CY2021	zyme	Licensing Agreement Noncash Consideration LicensingAgreementNoncashConsideration	0	usd
CY2020	zyme	Licensing Agreement Noncash Consideration LicensingAgreementNoncashConsideration	218000	usd
CY2022	us-gaap	Business Combination Contingent Consideration Arrangements Change In Amount Of Contingent Consideration Liability1 BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1	-250000	usd
CY2021	us-gaap	Business Combination Contingent Consideration Arrangements Change In Amount Of Contingent Consideration Liability1 BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1	213000	usd
CY2020	us-gaap	Business Combination Contingent Consideration Arrangements Change In Amount Of Contingent Consideration Liability1 BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1	307000	usd
CY2022	us-gaap	Unrealized Gain Loss On Investments UnrealizedGainLossOnInvestments	0	usd
CY2021	us-gaap	Unrealized Gain Loss On Investments UnrealizedGainLossOnInvestments	167000	usd
CY2020	us-gaap	Unrealized Gain Loss On Investments UnrealizedGainLossOnInvestments	0	usd
CY2022	us-gaap	Foreign Currency Transaction Gain Loss Unrealized ForeignCurrencyTransactionGainLossUnrealized	1956000	usd
CY2021	us-gaap	Foreign Currency Transaction Gain Loss Unrealized ForeignCurrencyTransactionGainLossUnrealized	433000	usd
CY2020	us-gaap	Foreign Currency Transaction Gain Loss Unrealized ForeignCurrencyTransactionGainLossUnrealized	453000	usd
CY2022	us-gaap	Increase Decrease In Accounts Receivable IncreaseDecreaseInAccountsReceivable	17509000	usd
CY2021	us-gaap	Increase Decrease In Accounts Receivable IncreaseDecreaseInAccountsReceivable	266000	usd
CY2020	us-gaap	Increase Decrease In Accounts Receivable IncreaseDecreaseInAccountsReceivable	13107000	usd
CY2022	us-gaap	Increase Decrease In Prepaid Deferred Expense And Other Assets IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets	2059000	usd
CY2021	us-gaap	Increase Decrease In Prepaid Deferred Expense And Other Assets IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets	15792000	usd
CY2020	us-gaap	Increase Decrease In Prepaid Deferred Expense And Other Assets IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets	3519000	usd
CY2022	us-gaap	Increase Decrease In Accounts Payable And Accrued Liabilities IncreaseDecreaseInAccountsPayableAndAccruedLiabilities	26479000	usd
CY2021	us-gaap	Increase Decrease In Accounts Payable And Accrued Liabilities IncreaseDecreaseInAccountsPayableAndAccruedLiabilities	16477000	usd
CY2020	us-gaap	Increase Decrease In Accounts Payable And Accrued Liabilities IncreaseDecreaseInAccountsPayableAndAccruedLiabilities	7618000	usd
CY2022	zyme	Increase Decrease In Operating Lease Liabilities IncreaseDecreaseInOperatingLeaseLiabilities	-3736000	usd
CY2021	zyme	Increase Decrease In Operating Lease Liabilities IncreaseDecreaseInOperatingLeaseLiabilities	-26000	usd
CY2020	zyme	Increase Decrease In Operating Lease Liabilities IncreaseDecreaseInOperatingLeaseLiabilities	-1140000	usd
CY2022	us-gaap	Increase Decrease In Income Taxes IncreaseDecreaseInIncomeTaxes	840000	usd
CY2021	us-gaap	Increase Decrease In Income Taxes IncreaseDecreaseInIncomeTaxes	0	usd
CY2020	us-gaap	Increase Decrease In Income Taxes IncreaseDecreaseInIncomeTaxes	0	usd
CY2022	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	144109000	usd
CY2021	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-192451000	usd
CY2020	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-151403000	usd
CY2022	us-gaap	Proceeds From Issuance Of Common Stock ProceedsFromIssuanceOfCommonStock	107534000	usd
CY2021	us-gaap	Proceeds From Issuance Of Common Stock ProceedsFromIssuanceOfCommonStock	0	usd
CY2020	us-gaap	Proceeds From Issuance Of Common Stock ProceedsFromIssuanceOfCommonStock	300910000	usd
CY2022	us-gaap	Proceeds From Issuance Of Shares Under Incentive And Share Based Compensation Plans Including Stock Options ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlansIncludingStockOptions	255000	usd
CY2021	us-gaap	Proceeds From Issuance Of Shares Under Incentive And Share Based Compensation Plans Including Stock Options ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlansIncludingStockOptions	6428000	usd
CY2020	us-gaap	Proceeds From Issuance Of Shares Under Incentive And Share Based Compensation Plans Including Stock Options ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlansIncludingStockOptions	7111000	usd
CY2022	zyme	Proceeds From Issuance Of Shares Under Employee Share Purchase Plan ProceedsFromIssuanceOfSharesUnderEmployeeSharePurchasePlan	1403000	usd
CY2021	zyme	Proceeds From Issuance Of Shares Under Employee Share Purchase Plan ProceedsFromIssuanceOfSharesUnderEmployeeSharePurchasePlan	2070000	usd
CY2020	zyme	Proceeds From Issuance Of Shares Under Employee Share Purchase Plan ProceedsFromIssuanceOfSharesUnderEmployeeSharePurchasePlan	1111000	usd
CY2022	zyme	Payments Of Deferred Financing Fees PaymentsOfDeferredFinancingFees	596000	usd
CY2021	zyme	Payments Of Deferred Financing Fees PaymentsOfDeferredFinancingFees	470000	usd
CY2020	zyme	Payments Of Deferred Financing Fees PaymentsOfDeferredFinancingFees	113000	usd
CY2022	us-gaap	Finance Lease Principal Payments FinanceLeasePrincipalPayments	14000	usd
CY2021	us-gaap	Finance Lease Principal Payments FinanceLeasePrincipalPayments	17000	usd
CY2020	us-gaap	Finance Lease Principal Payments FinanceLeasePrincipalPayments	41000	usd
CY2022	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	108582000	usd
CY2021	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	8011000	usd
CY2020	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	308978000	usd
CY2022	us-gaap	Payments For Proceeds From Short Term Investments PaymentsForProceedsFromShortTermInvestments	40724000	usd
CY2021	us-gaap	Payments For Proceeds From Short Term Investments PaymentsForProceedsFromShortTermInvestments	-157881000	usd
CY2020	us-gaap	Payments For Proceeds From Short Term Investments PaymentsForProceedsFromShortTermInvestments	-13325000	usd
CY2022	us-gaap	Payments To Acquire Longterm Investments PaymentsToAcquireLongtermInvestments	0	usd
CY2021	us-gaap	Payments To Acquire Longterm Investments PaymentsToAcquireLongtermInvestments	0	usd
CY2020	us-gaap	Payments To Acquire Longterm Investments PaymentsToAcquireLongtermInvestments	50500000	usd
CY2022	us-gaap	Payments To Acquire Property Plant And Equipment PaymentsToAcquirePropertyPlantAndEquipment	8150000	usd
CY2021	us-gaap	Payments To Acquire Property Plant And Equipment PaymentsToAcquirePropertyPlantAndEquipment	12404000	usd
CY2020	us-gaap	Payments To Acquire Property Plant And Equipment PaymentsToAcquirePropertyPlantAndEquipment	4310000	usd
CY2022	us-gaap	Payments To Acquire Intangible Assets PaymentsToAcquireIntangibleAssets	4975000	usd
CY2021	us-gaap	Payments To Acquire Intangible Assets PaymentsToAcquireIntangibleAssets	881000	usd
CY2020	us-gaap	Payments To Acquire Intangible Assets PaymentsToAcquireIntangibleAssets	1955000	usd
CY2022	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	-53849000	usd
CY2021	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	144596000	usd
CY2020	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	-43440000	usd
CY2022	us-gaap	Effect Of Exchange Rate On Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	203000	usd
CY2021	us-gaap	Effect Of Exchange Rate On Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	-325000	usd
CY2020	us-gaap	Effect Of Exchange Rate On Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	-550000	usd
CY2022	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect	199045000	usd
CY2021	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect	-40169000	usd
CY2020	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect	113585000	usd
CY2021Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	201867000	usd
CY2020Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	242036000	usd
CY2019Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	128451000	usd
CY2022Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	400912000	usd
CY2021Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	201867000	usd
CY2020Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	242036000	usd
CY2022	us-gaap	Right Of Use Asset Obtained In Exchange For Operating Lease Liability RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability	72000	usd
CY2021	us-gaap	Right Of Use Asset Obtained In Exchange For Operating Lease Liability RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability	24609000	usd
CY2020	us-gaap	Right Of Use Asset Obtained In Exchange For Operating Lease Liability RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability	2407000	usd
CY2022	us-gaap	Capital Expenditures Incurred But Not Yet Paid CapitalExpendituresIncurredButNotYetPaid	957000	usd
CY2021	us-gaap	Capital Expenditures Incurred But Not Yet Paid CapitalExpendituresIncurredButNotYetPaid	1933000	usd
CY2020	us-gaap	Capital Expenditures Incurred But Not Yet Paid CapitalExpendituresIncurredButNotYetPaid	130000	usd
CY2022	us-gaap	Nature Of Operations NatureOfOperations	Nature of Operations<div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Zymeworks Inc. (the “Company” or “Zymeworks”) is a clinical-stage biopharmaceutical company dedicated to the development of next-generation multifunctional biotherapeutics. Zymeworks BC Inc. (previously known as "Zymeworks Inc.") was incorporated on September 8, 2003 under the laws of the Canada Business Corporations Act. On October 22, 2003, the Company was registered as an extra-provincial company under the Company Act (British Columbia). On May 2, 2017, the Company continued under the Business Corporations Act (British Columbia).</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Since its inception, the Company has devoted substantially all of its resources to research and development activities, including developing its therapeutic platforms and identifying and developing potential product candidates by undertaking preclinical studies and clinical trials. The Company supports these activities through general and administrative support, as well as by raising capital, conducting business planning and protecting its intellectual property. </span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On July 15, 2022, the Company announced its intention to become a Delaware corporation, subject to receipt of necessary shareholder, stock exchange, and court approvals (the "Redomicile Transactions"). The Redomicile Transactions were completed on October 13, 2022. On October 13, 2022, the Company changed its name to Zymeworks BC Inc. Unless the context otherwise requires or otherwise expressly states, all references in the accompanying consolidated financial statements to “Zymeworks,” the “Company,” “we,” “us” and “our” (i) for periods until completion of the Redomicile Transactions, refer to Zymeworks BC Inc. and its subsidiaries and (ii) for periods after completion of the Redomicile Transactions, refer to Zymeworks Inc. (formerly known as Zymeworks Delaware Inc.) and its subsidiaries. </span></div>To effect the Redomicile Transactions, the Company conducted a share exchange, pursuant to which holders of the Company's common shares exchanged their common shares in the Company for shares of common stock of Zymeworks Inc. (formerly known as Zymeworks Delaware Inc.) or, at their election with respect to all or a portion of their common shares in the Company and subject to applicable eligibility criteria and an overall cap, exchangeable shares (the “Exchangeable Shares”) in the capital of a newly formed indirect subsidiary of Zymeworks Inc. A special meeting of Company security holders was held on October 7, 2022 to approve the Redomicile Transactions. The Redomicile Transactions were governed by a transaction agreement dated July 14, 2022, as restated and amended on August 18, 2022 (the “Restated and Amended Transaction Agreement”), by and among the Company and its direct or indirect subsidiaries Zymeworks Inc., Zymeworks CallCo ULC and Zymeworks ExchangeCo Ltd., including a plan of arrangement included as Exhibit A to the Restated and Amended Transaction Agreement (the “Plan of Arrangement”).
CY2022	us-gaap	Use Of Estimates UseOfEstimates	<div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Use of Estimates</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The preparation of consolidated financial statements in accordance with U.S. GAAP requires the Company to make estimates and judgments in certain circumstances that affect the reported amounts of assets, liabilities, revenue and expenses, and related disclosure of contingent assets and liabilities. On an ongoing basis, the Company evaluates its estimates, most notably those related to revenue recognition including estimated timing of completion of performance obligations required to meet revenue recognition criteria, accrual of expenses including clinical and preclinical study expense accruals, stock-based compensation, valuation allowance for deferred taxes, benefits under the Scientific Research and Experimental Development (“SR&ED”) program, and other contingencies. Management bases its estimates on historical experience and on various other assumptions that it believes to be reasonable under the circumstances. Actual results could differ from these estimates.</span></div>
CY2022	us-gaap	Number Of Operating Segments NumberOfOperatingSegments	1	segment
CY2022	us-gaap	Net Income Loss Available To Common Stockholders Basic NetIncomeLossAvailableToCommonStockholdersBasic	124341000	usd
CY2021	us-gaap	Net Income Loss Available To Common Stockholders Basic NetIncomeLossAvailableToCommonStockholdersBasic	-211843000	usd
CY2020	us-gaap	Net Income Loss Available To Common Stockholders Basic NetIncomeLossAvailableToCommonStockholdersBasic	-180552000	usd
CY2022	zyme	Fair Value Option Adjustment For Change In Fair Value Of Liability Classified Stock Options FairValueOptionAdjustmentForChangeInFairValueOfLiabilityClassifiedStockOptions	-231000	usd
CY2022	us-gaap	Goodwill Impairment Loss GoodwillImpairmentLoss	0	usd
CY2021	zyme	Fair Value Option Adjustment For Change In Fair Value Of Liability Classified Stock Options FairValueOptionAdjustmentForChangeInFairValueOfLiabilityClassifiedStockOptions	-28534000	usd
CY2020	zyme	Fair Value Option Adjustment For Change In Fair Value Of Liability Classified Stock Options FairValueOptionAdjustmentForChangeInFairValueOfLiabilityClassifiedStockOptions	0	usd
CY2022	us-gaap	Net Income Loss Available To Common Stockholders Diluted NetIncomeLossAvailableToCommonStockholdersDiluted	124110000	usd
CY2021	us-gaap	Net Income Loss Available To Common Stockholders Diluted NetIncomeLossAvailableToCommonStockholdersDiluted	-240377000	usd
CY2020	us-gaap	Net Income Loss Available To Common Stockholders Diluted NetIncomeLossAvailableToCommonStockholdersDiluted	-180552000	usd
CY2022	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	65194775	shares
CY2021	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	51553869	shares
CY2020	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	50382497	shares
CY2022	us-gaap	Incremental Common Shares Attributable To Share Based Payment Arrangements IncrementalCommonSharesAttributableToShareBasedPaymentArrangements	53535	shares
CY2021	us-gaap	Incremental Common Shares Attributable To Share Based Payment Arrangements IncrementalCommonSharesAttributableToShareBasedPaymentArrangements	0	shares
CY2020	us-gaap	Incremental Common Shares Attributable To Share Based Payment Arrangements IncrementalCommonSharesAttributableToShareBasedPaymentArrangements	0	shares
CY2022	zyme	Incremental Common Shares Attributable To Dilutive Effect Of Share Based Payment Arrangements Liability Classified IncrementalCommonSharesAttributableToDilutiveEffectOfShareBasedPaymentArrangementsLiabilityClassified	874	shares
CY2021	zyme	Incremental Common Shares Attributable To Dilutive Effect Of Share Based Payment Arrangements Liability Classified IncrementalCommonSharesAttributableToDilutiveEffectOfShareBasedPaymentArrangementsLiabilityClassified	577727	shares
CY2020	zyme	Incremental Common Shares Attributable To Dilutive Effect Of Share Based Payment Arrangements Liability Classified IncrementalCommonSharesAttributableToDilutiveEffectOfShareBasedPaymentArrangementsLiabilityClassified	0	shares
CY2022	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	65249184	shares
CY2021	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	52131596	shares
CY2020	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	50382497	shares
CY2022	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	1.91
CY2021	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-4.11
CY2020	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-3.58
CY2022	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	1.90
CY2021	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-4.61
CY2020	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-3.58
CY2022	us-gaap	Impairment Of Intangible Assets Excluding Goodwill ImpairmentOfIntangibleAssetsExcludingGoodwill	0	usd
CY2021	us-gaap	Impairment Of Intangible Assets Excluding Goodwill ImpairmentOfIntangibleAssetsExcludingGoodwill	0	usd
CY2020	us-gaap	Impairment Of Intangible Assets Excluding Goodwill ImpairmentOfIntangibleAssetsExcludingGoodwill	0	usd
CY2022	us-gaap	Number Of Reporting Units NumberOfReportingUnits	1	reportingunit
CY2022Q4	us-gaap	Property Plant And Equipment Gross PropertyPlantAndEquipmentGross	38012000	usd
CY2021Q4	us-gaap	Property Plant And Equipment Gross PropertyPlantAndEquipmentGross	36844000	usd
CY2022Q4	us-gaap	Accumulated Depreciation Depletion And Amortization Property Plant And Equipment AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment	13299000	usd
CY2021Q4	us-gaap	Accumulated Depreciation Depletion And Amortization Property Plant And Equipment AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment	14061000	usd
CY2022Q4	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	24713000	usd
CY2021Q4	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	22783000	usd
CY2022	us-gaap	Depreciation Depreciation	6220000	usd
CY2021	us-gaap	Depreciation Depreciation	3739000	usd
CY2020	us-gaap	Depreciation Depreciation	3355000	usd
CY2022Q4	us-gaap	Finite Lived Intangible Assets Gross FiniteLivedIntangibleAssetsGross	22927000	usd
CY2021Q4	us-gaap	Finite Lived Intangible Assets Gross FiniteLivedIntangibleAssetsGross	17719000	usd
CY2022Q4	us-gaap	Finite Lived Intangible Assets Accumulated Amortization FiniteLivedIntangibleAssetsAccumulatedAmortization	14172000	usd
CY2021Q4	us-gaap	Finite Lived Intangible Assets Accumulated Amortization FiniteLivedIntangibleAssetsAccumulatedAmortization	13881000	usd
CY2022Q4	us-gaap	Finite Lived Intangible Assets Net FiniteLivedIntangibleAssetsNet	8755000	usd
CY2021Q4	us-gaap	Finite Lived Intangible Assets Net FiniteLivedIntangibleAssetsNet	3838000	usd
CY2022	us-gaap	Amortization Of Intangible Assets AmortizationOfIntangibleAssets	1015000	usd
CY2021	us-gaap	Amortization Of Intangible Assets AmortizationOfIntangibleAssets	2793000	usd
CY2020	us-gaap	Amortization Of Intangible Assets AmortizationOfIntangibleAssets	4160000	usd
CY2022Q4	us-gaap	Finite Lived Intangible Assets Amortization Expense Next Twelve Months FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths	2702000	usd
CY2022Q4	us-gaap	Finite Lived Intangible Assets Amortization Expense Year Two FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo	2683000	usd
CY2022Q4	us-gaap	Finite Lived Intangible Assets Amortization Expense Year Three FiniteLivedIntangibleAssetsAmortizationExpenseYearThree	2259000	usd
CY2022Q4	us-gaap	Finite Lived Intangible Assets Amortization Expense Year Four FiniteLivedIntangibleAssetsAmortizationExpenseYearFour	427000	usd
CY2022Q4	us-gaap	Finite Lived Intangible Assets Amortization Expense Year Five FiniteLivedIntangibleAssetsAmortizationExpenseYearFive	213000	usd
CY2022Q4	zyme	Finite Lived Intangible Asset Expected Amortization FiniteLivedIntangibleAssetExpectedAmortization	8284000	usd
CY2022Q4	us-gaap	Accounts Payable Trade Current AccountsPayableTradeCurrent	7863000	usd
CY2021Q4	us-gaap	Accounts Payable Trade Current AccountsPayableTradeCurrent	5174000	usd
CY2022Q4	zyme	Accrued Research Expenses Current AccruedResearchExpensesCurrent	39358000	usd
CY2021Q4	zyme	Accrued Research Expenses Current AccruedResearchExpensesCurrent	50963000	usd
CY2022Q4	us-gaap	Sales And Excise Tax Payable Current SalesAndExciseTaxPayableCurrent	16244000	usd
CY2021Q4	us-gaap	Sales And Excise Tax Payable Current SalesAndExciseTaxPayableCurrent	0	usd
CY2022Q4	us-gaap	Employee Related Liabilities Current EmployeeRelatedLiabilitiesCurrent	14365000	usd
CY2022Q4	us-gaap	Other Accrued Liabilities Noncurrent OtherAccruedLiabilitiesNoncurrent	682000	usd
CY2021Q4	us-gaap	Finance Lease Liability Noncurrent FinanceLeaseLiabilityNoncurrent	100000	usd
CY2021Q4	us-gaap	Employee Related Liabilities Current EmployeeRelatedLiabilitiesCurrent	3346000	usd
CY2022Q4	zyme	Accrued Legal And Professional Fees Current AccruedLegalAndProfessionalFeesCurrent	7799000	usd
CY2021Q4	zyme	Accrued Legal And Professional Fees Current AccruedLegalAndProfessionalFeesCurrent	1064000	usd
CY2022Q4	us-gaap	Other Accounts Payable And Accrued Liabilities OtherAccountsPayableAndAccruedLiabilities	1839000	usd
CY2021Q4	us-gaap	Other Accounts Payable And Accrued Liabilities OtherAccountsPayableAndAccruedLiabilities	2242000	usd
CY2022Q4	us-gaap	Accounts Payable And Accrued Liabilities Current AccountsPayableAndAccruedLiabilitiesCurrent	87468000	usd
CY2021Q4	us-gaap	Accounts Payable And Accrued Liabilities Current AccountsPayableAndAccruedLiabilitiesCurrent	62789000	usd
CY2022Q4	us-gaap	Business Combination Contingent Consideration Liability Noncurrent BusinessCombinationContingentConsiderationLiabilityNoncurrent	1248000	usd
CY2021Q4	us-gaap	Business Combination Contingent Consideration Liability Noncurrent BusinessCombinationContingentConsiderationLiabilityNoncurrent	1498000	usd
CY2022Q4	zyme	Liabilities From In Licensing Agreements LiabilitiesFromInLicensingAgreements	1047000	usd
CY2021Q4	zyme	Liabilities From In Licensing Agreements LiabilitiesFromInLicensingAgreements	1150000	usd
CY2022Q4	us-gaap	Finance Lease Liability Noncurrent FinanceLeaseLiabilityNoncurrent	124000	usd
CY2021Q4	us-gaap	Other Accrued Liabilities Noncurrent OtherAccruedLiabilitiesNoncurrent	0	usd
CY2022Q4	us-gaap	Liabilities Other Than Longterm Debt Noncurrent LiabilitiesOtherThanLongtermDebtNoncurrent	3101000	usd
CY2021Q4	us-gaap	Liabilities Other Than Longterm Debt Noncurrent LiabilitiesOtherThanLongtermDebtNoncurrent	2748000	usd
CY2022Q4	zyme	All Classes Of Stock Shares Authorized AllClassesOfStockSharesAuthorized	1000000000	shares
CY2022Q4	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	900000000	shares
CY2022Q4	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.00001
CY2021Q4	us-gaap	Preferred Stock Shares Authorized PreferredStockSharesAuthorized	100000000	shares
CY2022Q4	us-gaap	Preferred Stock Shares Authorized PreferredStockSharesAuthorized	100000000	shares
CY2022Q4	us-gaap	Preferred Stock Par Or Stated Value Per Share PreferredStockParOrStatedValuePerShare	0.00001
CY2021Q4	us-gaap	Preferred Stock Par Or Stated Value Per Share PreferredStockParOrStatedValuePerShare	0.00001
CY2022Q4	us-gaap	Preferred Stock Shares Outstanding PreferredStockSharesOutstanding	1	shares
CY2022Q4	us-gaap	Preferred Stock Shares Issued PreferredStockSharesIssued	1	shares
CY2022Q4	us-gaap	Preferred Stock Par Or Stated Value Per Share PreferredStockParOrStatedValuePerShare	0.00001
CY2021Q4	us-gaap	Preferred Stock Par Or Stated Value Per Share PreferredStockParOrStatedValuePerShare	0.00001
CY2022Q4	us-gaap	Temporary Equity Shares Outstanding TemporaryEquitySharesOutstanding	1424533	shares
CY2019Q2	us-gaap	Class Of Warrant Or Right Exercise Price Of Warrants Or Rights1 ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1	0.0001
CY2022Q3	zyme	Warrants Exercised During Period WarrantsExercisedDuringPeriod	3787737	shares
CY2021Q4	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Nonvested Number Of Shares SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfShares	773593	shares
CY2021Q4	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Nonvested Weighted Average Grant Date Fair Value SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValue	27.97
CY2022Q3	us-gaap	Stock Issued During Period Shares Conversion Of Convertible Securities StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities	3787675	shares
CY2022Q3	us-gaap	Stock Issued During Period Value Conversion Of Convertible Securities StockIssuedDuringPeriodValueConversionOfConvertibleSecurities	57858000	usd
CY2022Q2	us-gaap	Class Of Warrant Or Right Exercise Price Of Warrants Or Rights1 ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1	74.00
CY2022	zyme	Share Based Payment Arrangement Individual Penalty Threshold Percentage ShareBasedPaymentArrangementIndividualPenaltyThresholdPercentage	0.10
CY2022	zyme	Share Based Payment Arrangement Institutional Investors Penalty Threshold Percentage ShareBasedPaymentArrangementInstitutionalInvestorsPenaltyThresholdPercentage	0.20
CY2018Q2	zyme	Maximum Number Of Common Shares Reserved For Issuance MaximumNumberOfCommonSharesReservedForIssuance	5686097	shares
CY2018Q1	zyme	Common Stock Shares Issuable Upon Exercise Of Stock Option CommonStockSharesIssuableUponExerciseOfStockOption	3686097	shares
CY2022Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Number Of Shares Available For Grant ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant	3205132	shares
CY2021Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Number Of Shares Available For Grant ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant	952632	shares
CY2018Q2	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Percentage Of Outstanding Stock Maximum ShareBasedCompensationArrangementByShareBasedPaymentAwardPercentageOfOutstandingStockMaximum	0.20
CY2022	zyme	Share Based Compensation Arrangement By Share Based Payment Award Exercisable Period ShareBasedCompensationArrangementByShareBasedPaymentAwardExercisablePeriod	P10Y
CY2022	us-gaap	Proceeds From Stock Options Exercised ProceedsFromStockOptionsExercised	255000	usd
CY2021	us-gaap	Proceeds From Stock Options Exercised ProceedsFromStockOptionsExercised	6428000	usd
CY2020	us-gaap	Proceeds From Stock Options Exercised ProceedsFromStockOptionsExercised	7111000	usd
CY2021Q4	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Nonvested Weighted Average Grant Date Fair Value SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValue	21.98
CY2022	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Gross ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross	917035	shares
CY2022	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Weighted Average Grant Date Fair Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue	5.80
CY2022	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Weighted Average Grant Date Fair Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue	4.28
CY2022	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Vested Number Of Shares SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares	355428	shares
CY2022	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Vested Weighted Average Grant Date Fair Value SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedWeightedAverageGrantDateFairValue	19.61
CY2022	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Vested Weighted Average Grant Date Fair Value SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedWeightedAverageGrantDateFairValue	14.47
CY2022	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Nonvested Options Forfeited Number Of Shares SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedOptionsForfeitedNumberOfShares	562660	shares
CY2022	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Nonvested Options Forfeited Weighted Average Grant Date Fair Value SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedOptionsForfeitedWeightedAverageGrantDateFairValue	19.83
CY2022	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Nonvested Options Forfeited Weighted Average Grant Date Fair Value SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedOptionsForfeitedWeightedAverageGrantDateFairValue	14.64
CY2022Q4	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Nonvested Number Of Shares SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfShares	772540	shares
CY2022Q4	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Nonvested Weighted Average Grant Date Fair Value SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValue	11.40
CY2022Q4	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Nonvested Weighted Average Grant Date Fair Value SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValue	8.41
CY2022	us-gaap	Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue	9516000	usd
CY2022Q4	zyme	Derivative Liability Classified Stock Options And Espp DerivativeLiabilityClassifiedStockOptionsAndESPP	3261000	usd
CY2021	us-gaap	Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue	38275000	usd
CY2021Q4	zyme	Derivative Liability Classified Stock Options And Espp DerivativeLiabilityClassifiedStockOptionsAndESPP	27517000	usd
CY2020	us-gaap	Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue	26945000	usd
CY2020Q4	zyme	Derivative Liability Classified Stock Options And Espp DerivativeLiabilityClassifiedStockOptionsAndESPP	2171000	usd
CY2022	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Dividend Rate ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate	0
CY2021	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Dividend Rate ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate	0
CY2020	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Dividend Rate ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate	0
CY2022	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Weighted Average Volatility Rate ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsWeightedAverageVolatilityRate	0.772
CY2021	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Weighted Average Volatility Rate ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsWeightedAverageVolatilityRate	0.803
CY2020	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Weighted Average Volatility Rate ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsWeightedAverageVolatilityRate	0.768
CY2022	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate	0.0212
CY2021	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate	0.0102
CY2020	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate	0.0066
CY2022	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Fair Value Assumptions Expected Term1 SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1	P5Y11M4D
CY2021	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Fair Value Assumptions Expected Term1 SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1	P6Y18D
CY2020	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Fair Value Assumptions Expected Term1 SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1	P6Y14D
CY2022	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Exercises In Period Total Intrinsic Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue	53000	usd
CY2021	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Exercises In Period Total Intrinsic Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue	10998000	usd
CY2020	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Exercises In Period Total Intrinsic Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue	19446000	usd
CY2022	zyme	Share Based Compensation By Share Based Payment Award Unamortized Compensation Expense ShareBasedCompensationByShareBasedPaymentAwardUnamortizedCompensationExpense	13879000	usd
CY2022	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Vested And Expected To Vest Outstanding Weighted Average Remaining Contractual Term1 SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1	P1Y6M
CY2022	zyme	Accrued Investment Tax Credit AccruedInvestmentTaxCredit	0	usd
CY2022	us-gaap	Revenue From Contract With Customer Excluding Assessed Tax RevenueFromContractWithCustomerExcludingAssessedTax	412482000	usd
CY2021	us-gaap	Revenue From Contract With Customer Excluding Assessed Tax RevenueFromContractWithCustomerExcludingAssessedTax	26680000	usd
CY2020	us-gaap	Revenue From Contract With Customer Excluding Assessed Tax RevenueFromContractWithCustomerExcludingAssessedTax	38951000	usd
CY2022Q4	us-gaap	Contract With Customer Asset Net ContractWithCustomerAssetNet	3000000	usd
CY2021Q4	us-gaap	Contract With Customer Asset Net ContractWithCustomerAssetNet	0	usd
CY2022Q4	us-gaap	Contract With Customer Liability ContractWithCustomerLiability	32941000	usd
CY2021Q4	us-gaap	Contract With Customer Liability ContractWithCustomerLiability	32941000	usd
CY2022Q4	us-gaap	Contract With Customer Liability Current ContractWithCustomerLiabilityCurrent	2353000	usd
CY2021Q4	us-gaap	Contract With Customer Liability Current ContractWithCustomerLiabilityCurrent	0	usd
CY2021	us-gaap	Current Income Tax Expense Benefit CurrentIncomeTaxExpenseBenefit	437000	usd
CY2020	us-gaap	Current Income Tax Expense Benefit CurrentIncomeTaxExpenseBenefit	292000	usd
CY2022	us-gaap	Foreign Currency Transaction Gain Loss Before Tax ForeignCurrencyTransactionGainLossBeforeTax	1152000	usd
CY2021	us-gaap	Foreign Currency Transaction Gain Loss Before Tax ForeignCurrencyTransactionGainLossBeforeTax	1191000	usd
CY2020	us-gaap	Foreign Currency Transaction Gain Loss Before Tax ForeignCurrencyTransactionGainLossBeforeTax	1683000	usd
CY2022	us-gaap	Other Nonoperating Income Expense OtherNonoperatingIncomeExpense	-42000	usd
CY2021	us-gaap	Other Nonoperating Income Expense OtherNonoperatingIncomeExpense	118000	usd
CY2020	us-gaap	Other Nonoperating Income Expense OtherNonoperatingIncomeExpense	-35000	usd
CY2022	us-gaap	Nonoperating Income Expense NonoperatingIncomeExpense	1110000	usd
CY2021	us-gaap	Nonoperating Income Expense NonoperatingIncomeExpense	1309000	usd
CY2020	us-gaap	Nonoperating Income Expense NonoperatingIncomeExpense	1648000	usd
CY2022	us-gaap	Current Income Tax Expense Benefit CurrentIncomeTaxExpenseBenefit	8953000	usd
CY2022	us-gaap	Deferred Income Tax Expense Benefit DeferredIncomeTaxExpenseBenefit	1940000	usd
CY2021	us-gaap	Deferred Income Tax Expense Benefit DeferredIncomeTaxExpenseBenefit	-953000	usd
CY2020	us-gaap	Deferred Income Tax Expense Benefit DeferredIncomeTaxExpenseBenefit	137000	usd
CY2022	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	10893000	usd
CY2021	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	-516000	usd
CY2020	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	429000	usd
CY2022	us-gaap	Effective Income Tax Rate Reconciliation Tax Settlements State And Local EffectiveIncomeTaxRateReconciliationTaxSettlementsStateAndLocal	0.21
CY2021	us-gaap	Effective Income Tax Rate Reconciliation Tax Settlements State And Local EffectiveIncomeTaxRateReconciliationTaxSettlementsStateAndLocal	0.21
CY2020	us-gaap	Effective Income Tax Rate Reconciliation Tax Settlements State And Local EffectiveIncomeTaxRateReconciliationTaxSettlementsStateAndLocal	0.21
CY2022	us-gaap	Income Tax Reconciliation Income Tax Expense Benefit At Federal Statutory Income Tax Rate IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate	28429000	usd
CY2021	us-gaap	Income Tax Reconciliation Income Tax Expense Benefit At Federal Statutory Income Tax Rate IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate	-44620000	usd
CY2020	us-gaap	Income Tax Reconciliation Income Tax Expense Benefit At Federal Statutory Income Tax Rate IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate	-37821000	usd
CY2022	us-gaap	Income Tax Reconciliation Nondeductible Expense IncomeTaxReconciliationNondeductibleExpense	9745000	usd
CY2021	us-gaap	Income Tax Reconciliation Nondeductible Expense IncomeTaxReconciliationNondeductibleExpense	798000	usd
CY2020	us-gaap	Income Tax Reconciliation Nondeductible Expense IncomeTaxReconciliationNondeductibleExpense	7149000	usd
CY2022	us-gaap	Income Tax Reconciliation Foreign Income Tax Rate Differential IncomeTaxReconciliationForeignIncomeTaxRateDifferential	8365000	usd
CY2021	us-gaap	Income Tax Reconciliation Foreign Income Tax Rate Differential IncomeTaxReconciliationForeignIncomeTaxRateDifferential	-12175000	usd
CY2020	us-gaap	Income Tax Reconciliation Foreign Income Tax Rate Differential IncomeTaxReconciliationForeignIncomeTaxRateDifferential	-8949000	usd
CY2022	us-gaap	Income Tax Reconciliation Prior Year Income Taxes IncomeTaxReconciliationPriorYearIncomeTaxes	826000	usd
CY2021	us-gaap	Income Tax Reconciliation Prior Year Income Taxes IncomeTaxReconciliationPriorYearIncomeTaxes	33000	usd
CY2020	us-gaap	Income Tax Reconciliation Prior Year Income Taxes IncomeTaxReconciliationPriorYearIncomeTaxes	441000	usd
CY2022	us-gaap	Income Tax Reconciliation Change In Deferred Tax Assets Valuation Allowance IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance	-33526000	usd
CY2021	us-gaap	Income Tax Reconciliation Change In Deferred Tax Assets Valuation Allowance IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance	60260000	usd
CY2020	us-gaap	Income Tax Reconciliation Change In Deferred Tax Assets Valuation Allowance IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance	48411000	usd
CY2022	zyme	Income Tax Reconciliation Nondeductible Expense Share Issuance Costs In Equity IncomeTaxReconciliationNondeductibleExpenseShareIssuanceCostsInEquity	0	usd
CY2021	zyme	Income Tax Reconciliation Nondeductible Expense Share Issuance Costs In Equity IncomeTaxReconciliationNondeductibleExpenseShareIssuanceCostsInEquity	-2000	usd
CY2020	zyme	Income Tax Reconciliation Nondeductible Expense Share Issuance Costs In Equity IncomeTaxReconciliationNondeductibleExpenseShareIssuanceCostsInEquity	-5385000	usd
CY2022	us-gaap	Income Tax Reconciliation Tax Credits Research IncomeTaxReconciliationTaxCreditsResearch	3238000	usd
CY2021	us-gaap	Income Tax Reconciliation Tax Credits Research IncomeTaxReconciliationTaxCreditsResearch	5096000	usd
CY2020	us-gaap	Income Tax Reconciliation Tax Credits Research IncomeTaxReconciliationTaxCreditsResearch	4067000	usd
CY2022	us-gaap	Income Tax Reconciliation Other Adjustments IncomeTaxReconciliationOtherAdjustments	292000	usd
CY2021	us-gaap	Income Tax Reconciliation Other Adjustments IncomeTaxReconciliationOtherAdjustments	286000	usd
CY2020	us-gaap	Income Tax Reconciliation Other Adjustments IncomeTaxReconciliationOtherAdjustments	650000	usd
CY2022	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	10893000	usd
CY2021	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	-516000	usd
CY2020	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	429000	usd
CY2022Q4	zyme	Deferred Tax Assets Non Capital Loss Carry Forwards DeferredTaxAssetsNonCapitalLossCarryForwards	84948000	usd
CY2021Q4	zyme	Deferred Tax Assets Non Capital Loss Carry Forwards DeferredTaxAssetsNonCapitalLossCarryForwards	123554000	usd
CY2022Q4	us-gaap	Deferred Tax Assets Deferred Income DeferredTaxAssetsDeferredIncome	8893000	usd
CY2021Q4	us-gaap	Deferred Tax Assets Deferred Income DeferredTaxAssetsDeferredIncome	8894000	usd
CY2022Q4	zyme	Deferred Tax Assets Share Issue Costs DeferredTaxAssetsShareIssueCosts	4549000	usd
CY2021Q4	zyme	Deferred Tax Assets Share Issue Costs DeferredTaxAssetsShareIssueCosts	6058000	usd
CY2022Q4	us-gaap	Deferred Tax Assets Property Plant And Equipment DeferredTaxAssetsPropertyPlantAndEquipment	565000	usd
CY2021Q4	us-gaap	Deferred Tax Assets Property Plant And Equipment DeferredTaxAssetsPropertyPlantAndEquipment	1219000	usd
CY2022Q4	us-gaap	Deferred Tax Assets Goodwill And Intangible Assets DeferredTaxAssetsGoodwillAndIntangibleAssets	5930000	usd
CY2021Q4	us-gaap	Deferred Tax Assets Goodwill And Intangible Assets DeferredTaxAssetsGoodwillAndIntangibleAssets	2911000	usd
CY2022Q4	us-gaap	Deferred Tax Assets In Process Research And Development DeferredTaxAssetsInProcessResearchAndDevelopment	39957000	usd
CY2021Q4	us-gaap	Deferred Tax Assets In Process Research And Development DeferredTaxAssetsInProcessResearchAndDevelopment	35401000	usd
CY2022Q4	us-gaap	Deferred Tax Assets Tax Deferred Expense Reserves And Accruals Contingencies DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsContingencies	404000	usd
CY2021Q4	us-gaap	Deferred Tax Assets Tax Deferred Expense Reserves And Accruals Contingencies DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsContingencies	421000	usd
CY2022Q4	zyme	Deferred Tax Assets Stock Options DeferredTaxAssetsStockOptions	4344000	usd
CY2021Q4	zyme	Deferred Tax Assets Stock Options DeferredTaxAssetsStockOptions	4330000	usd
CY2022Q4	zyme	Deferred Tax Assets Operating Lease Liability DeferredTaxAssetsOperatingLeaseLiability	7008000	usd
CY2021Q4	zyme	Deferred Tax Assets Operating Lease Liability DeferredTaxAssetsOperatingLeaseLiability	7871000	usd
CY2022Q4	us-gaap	Deferred Tax Assets Other DeferredTaxAssetsOther	302000	usd
CY2021Q4	us-gaap	Deferred Tax Assets Other DeferredTaxAssetsOther	351000	usd
CY2022Q4	us-gaap	Deferred Tax Assets Gross DeferredTaxAssetsGross	156900000	usd
CY2021Q4	us-gaap	Deferred Tax Assets Gross DeferredTaxAssetsGross	191010000	usd
CY2022Q4	us-gaap	Deferred Tax Liabilities Property Plant And Equipment DeferredTaxLiabilitiesPropertyPlantAndEquipment	967000	usd
CY2021Q4	us-gaap	Deferred Tax Liabilities Property Plant And Equipment DeferredTaxLiabilitiesPropertyPlantAndEquipment	1085000	usd
CY2022Q4	us-gaap	Deferred Tax Liabilities Goodwill And Intangible Assets Intangible Assets DeferredTaxLiabilitiesGoodwillAndIntangibleAssetsIntangibleAssets	4759000	usd
CY2021Q4	us-gaap	Deferred Tax Liabilities Goodwill And Intangible Assets Intangible Assets DeferredTaxLiabilitiesGoodwillAndIntangibleAssetsIntangibleAssets	4760000	usd
CY2022Q4	zyme	Deferred Tax Liabilities Operating Lease Right Of Use Assets DeferredTaxLiabilitiesOperatingLeaseRightOfUseAssets	5758000	usd
CY2021Q4	zyme	Deferred Tax Liabilities Operating Lease Right Of Use Assets DeferredTaxLiabilitiesOperatingLeaseRightOfUseAssets	6685000	usd
CY2022Q4	zyme	Deferred Tax Liabilities Outside Basis Difference DeferredTaxLiabilitiesOutsideBasisDifference	1788000	usd
CY2021Q4	zyme	Deferred Tax Liabilities Outside Basis Difference DeferredTaxLiabilitiesOutsideBasisDifference	1573000	usd
CY2022Q4	us-gaap	Deferred Income Tax Liabilities DeferredIncomeTaxLiabilities	13272000	usd
CY2021Q4	us-gaap	Deferred Income Tax Liabilities DeferredIncomeTaxLiabilities	14103000	usd
CY2022Q4	zyme	Deferred Tax Assets Liabilities Before Valuation Allowance DeferredTaxAssetsLiabilitiesBeforeValuationAllowance	143628000	usd
CY2021Q4	zyme	Deferred Tax Assets Liabilities Before Valuation Allowance DeferredTaxAssetsLiabilitiesBeforeValuationAllowance	176907000	usd
CY2022Q4	us-gaap	Deferred Tax Assets Valuation Allowance DeferredTaxAssetsValuationAllowance	144071000	usd
CY2021Q4	us-gaap	Deferred Tax Assets Valuation Allowance DeferredTaxAssetsValuationAllowance	175410000	usd
CY2022Q4	us-gaap	Deferred Tax Liabilities DeferredTaxLiabilities	443000	usd
CY2021Q4	us-gaap	Deferred Tax Assets Liabilities Net DeferredTaxAssetsLiabilitiesNet	1497000	usd
CY2022Q4	us-gaap	Deferred Tax Assets Net DeferredTaxAssetsNet	1345000	usd
CY2021Q4	us-gaap	Deferred Tax Assets Net DeferredTaxAssetsNet	3070000	usd
CY2022Q4	us-gaap	Operating Lease Liability Current OperatingLeaseLiabilityCurrent	3322000	usd
CY2022Q4	us-gaap	Deferred Income Tax Liabilities Net DeferredIncomeTaxLiabilitiesNet	1788000	usd
CY2021Q4	us-gaap	Deferred Income Tax Liabilities Net DeferredIncomeTaxLiabilitiesNet	1573000	usd
CY2022Q4	us-gaap	Deferred Tax Liabilities DeferredTaxLiabilities	443000	usd
CY2021Q4	us-gaap	Deferred Tax Assets Liabilities Net DeferredTaxAssetsLiabilitiesNet	1497000	usd
CY2022Q4	us-gaap	Deferred Tax Assets Operating Loss Carryforwards DeferredTaxAssetsOperatingLossCarryforwards	314700000	usd
CY2021Q4	us-gaap	Deferred Tax Assets Operating Loss Carryforwards DeferredTaxAssetsOperatingLossCarryforwards	457600000	usd
CY2022Q4	us-gaap	Operating Loss Carryforwards OperatingLossCarryforwards	314653000	usd
CY2021Q4	us-gaap	Unrecognized Tax Benefits UnrecognizedTaxBenefits	3063000	usd
CY2020Q4	us-gaap	Unrecognized Tax Benefits UnrecognizedTaxBenefits	3063000	usd
CY2019Q4	us-gaap	Unrecognized Tax Benefits UnrecognizedTaxBenefits	3063000	usd
CY2022	us-gaap	Unrecognized Tax Benefits Increases Resulting From Prior Period Tax Positions UnrecognizedTaxBenefitsIncreasesResultingFromPriorPeriodTaxPositions	0	usd
CY2021	us-gaap	Unrecognized Tax Benefits Increases Resulting From Prior Period Tax Positions UnrecognizedTaxBenefitsIncreasesResultingFromPriorPeriodTaxPositions	0	usd
CY2020	us-gaap	Unrecognized Tax Benefits Increases Resulting From Prior Period Tax Positions UnrecognizedTaxBenefitsIncreasesResultingFromPriorPeriodTaxPositions	0	usd
CY2022	us-gaap	Unrecognized Tax Benefits Increases Resulting From Current Period Tax Positions UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions	0	usd
CY2021	us-gaap	Unrecognized Tax Benefits Increases Resulting From Current Period Tax Positions UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions	0	usd
CY2020	us-gaap	Unrecognized Tax Benefits Increases Resulting From Current Period Tax Positions UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions	0	usd
CY2022Q4	us-gaap	Unrecognized Tax Benefits UnrecognizedTaxBenefits	3063000	usd
CY2021Q4	us-gaap	Unrecognized Tax Benefits UnrecognizedTaxBenefits	3063000	usd
CY2020Q4	us-gaap	Unrecognized Tax Benefits UnrecognizedTaxBenefits	3063000	usd
CY2022Q4	us-gaap	Unrecognized Tax Benefits That Would Impact Effective Tax Rate UnrecognizedTaxBenefitsThatWouldImpactEffectiveTaxRate	0	usd
CY2020Q4	us-gaap	Unrecognized Tax Benefits That Would Impact Effective Tax Rate UnrecognizedTaxBenefitsThatWouldImpactEffectiveTaxRate	0	usd
CY2021Q4	us-gaap	Unrecognized Tax Benefits That Would Impact Effective Tax Rate UnrecognizedTaxBenefitsThatWouldImpactEffectiveTaxRate	0	usd
CY2021Q4	us-gaap	Operating Lease Liability Current OperatingLeaseLiabilityCurrent	1310000	usd
CY2022Q4	us-gaap	Operating Lease Liability Noncurrent OperatingLeaseLiabilityNoncurrent	24667000	usd
CY2021Q4	us-gaap	Operating Lease Liability Noncurrent OperatingLeaseLiabilityNoncurrent	30923000	usd
CY2022Q4	us-gaap	Operating Lease Liability OperatingLeaseLiability	27989000	usd
CY2021Q4	us-gaap	Operating Lease Liability OperatingLeaseLiability	32233000	usd
CY2022Q4	us-gaap	Finance Lease Liability Current FinanceLeaseLiabilityCurrent	16000	usd
CY2021Q4	us-gaap	Finance Lease Liability Current FinanceLeaseLiabilityCurrent	22000	usd
CY2022Q4	us-gaap	Finance Lease Liability Noncurrent FinanceLeaseLiabilityNoncurrent	124000	usd
CY2021Q4	us-gaap	Finance Lease Liability Noncurrent FinanceLeaseLiabilityNoncurrent	100000	usd
CY2022Q4	us-gaap	Finance Lease Liability FinanceLeaseLiability	140000	usd
CY2021Q4	us-gaap	Finance Lease Liability FinanceLeaseLiability	122000	usd
CY2022Q4	zyme	Lease Liability LeaseLiability	28129000	usd
CY2021Q4	zyme	Lease Liability LeaseLiability	32355000	usd
CY2022	us-gaap	Operating Lease Payments OperatingLeasePayments	4471000	usd
CY2022Q4	us-gaap	Lessee Operating Lease Liability Payments Due Next Rolling Twelve Months LesseeOperatingLeaseLiabilityPaymentsDueNextRollingTwelveMonths	4435000	usd
CY2022Q4	us-gaap	Lessee Operating Lease Liability Payments Due In Rolling Year Two LesseeOperatingLeaseLiabilityPaymentsDueInRollingYearTwo	4493000	usd
CY2022Q4	us-gaap	Lessee Operating Lease Liability Payments Due In Rolling Year Three LesseeOperatingLeaseLiabilityPaymentsDueInRollingYearThree	4611000	usd
CY2022Q4	us-gaap	Lessee Operating Lease Liability Payments Due In Rolling Year Four LesseeOperatingLeaseLiabilityPaymentsDueInRollingYearFour	4589000	usd
CY2022Q4	us-gaap	Lessee Operating Lease Liability Payments Due In Rolling Year Five LesseeOperatingLeaseLiabilityPaymentsDueInRollingYearFive	3357000	usd
CY2022Q4	us-gaap	Lessee Operating Lease Liability Payments Due After Rolling Year Five LesseeOperatingLeaseLiabilityPaymentsDueAfterRollingYearFive	11653000	usd
CY2022Q4	us-gaap	Lessee Operating Lease Liability Payments Due LesseeOperatingLeaseLiabilityPaymentsDue	33138000	usd
CY2022Q4	us-gaap	Lessee Operating Lease Liability Undiscounted Excess Amount LesseeOperatingLeaseLiabilityUndiscountedExcessAmount	5149000	usd
CY2022Q4	us-gaap	Operating Lease Liability OperatingLeaseLiability	27989000	usd
CY2022Q4	us-gaap	Operating Lease Weighted Average Remaining Lease Term1 OperatingLeaseWeightedAverageRemainingLeaseTerm1	P7Y9M18D
CY2022	us-gaap	Operating Lease Expense OperatingLeaseExpense	7795000	usd
CY2021	us-gaap	Operating Lease Expense OperatingLeaseExpense	5658000	usd
CY2020	us-gaap	Operating Lease Expense OperatingLeaseExpense	3595000	usd
CY2022	zyme	Fixed Lease Payment FixedLeasePayment	6609000	usd
CY2021	zyme	Fixed Lease Payment FixedLeasePayment	5323000	usd
CY2020	zyme	Fixed Lease Payment FixedLeasePayment	3156000	usd
CY2022	us-gaap	Variable Lease Payment VariableLeasePayment	1186000	usd
CY2021	us-gaap	Variable Lease Payment VariableLeasePayment	335000	usd
CY2020	us-gaap	Variable Lease Payment VariableLeasePayment	439000	usd
CY2022	us-gaap	Operating Lease Impairment Loss OperatingLeaseImpairmentLoss	0	usd
CY2021	us-gaap	Operating Lease Impairment Loss OperatingLeaseImpairmentLoss	0	usd
CY2022Q4	us-gaap	Assets Fair Value Disclosure AssetsFairValueDisclosure	291609000	usd
CY2022Q4	us-gaap	Financial Liabilities Fair Value Disclosure FinancialLiabilitiesFairValueDisclosure	1248000	usd
CY2021Q4	us-gaap	Assets Fair Value Disclosure AssetsFairValueDisclosure	112128000	usd
CY2021Q4	us-gaap	Financial Liabilities Fair Value Disclosure FinancialLiabilitiesFairValueDisclosure	1498000	usd
CY2021Q4	zyme	Contingent Consideration Liability Fair Value Disclosure ContingentConsiderationLiabilityFairValueDisclosure	1498000	usd
CY2022	zyme	Contingent Consideration Fair Value Adjustments ContingentConsiderationFairValueAdjustments	0	usd
CY2022	zyme	Contingent Consideration Liability Fair Value Disclosure Transfers ContingentConsiderationLiabilityFairValueDisclosureTransfers	250000	usd
CY2022Q4	zyme	Contingent Consideration Liability Fair Value Disclosure ContingentConsiderationLiabilityFairValueDisclosure	1248000	usd
CY2020Q4	zyme	Contingent Consideration Liability Fair Value Disclosure ContingentConsiderationLiabilityFairValueDisclosure	1285000	usd
CY2021	zyme	Contingent Consideration Fair Value Adjustments ContingentConsiderationFairValueAdjustments	213000	usd
CY2021	zyme	Contingent Consideration Liability Fair Value Disclosure Transfers ContingentConsiderationLiabilityFairValueDisclosureTransfers	0	usd
CY2021Q4	zyme	Contingent Consideration Liability Fair Value Disclosure ContingentConsiderationLiabilityFairValueDisclosure	1498000	usd
CY2022	us-gaap	Concentration Risk Credit Risk Financial Instrument Maximum Exposure ConcentrationRiskCreditRiskFinancialInstrumentMaximumExposure	33400000	usd
CY2021	us-gaap	Concentration Risk Credit Risk Financial Instrument Maximum Exposure ConcentrationRiskCreditRiskFinancialInstrumentMaximumExposure	15614000	usd
CY2022Q4	zyme	Net Monetary Assets Denominated In Foreign Currency NetMonetaryAssetsDenominatedInForeignCurrency	-1593000	usd
CY2022Q4	zyme	Net Monetary Assets Denominated In Foreign Currency NetMonetaryAssetsDenominatedInForeignCurrency	-2144000	cad
CY2022	us-gaap	Restructuring And Related Cost Number Of Positions Eliminated Period Percent RestructuringAndRelatedCostNumberOfPositionsEliminatedPeriodPercent	0.25
CY2022Q4	us-gaap	Restructuring Reserve RestructuringReserve	678000	usd

Files In Submission

Name	View Source	Status
0001937653-23-000011-index-headers.html	Edgar Link	pending
0001937653-23-000011-index.html	Edgar Link	pending
0001937653-23-000011.txt	Edgar Link	pending
0001937653-23-000011-xbrl.zip	Edgar Link	pending
Financial_Report.xlsx	Edgar Link	pending
image_5a.jpg	Edgar Link	pending
MetaLinks.json	Edgar Link	pending
R1.htm	Edgar Link	pending
R10.htm	Edgar Link	pending
R11.htm	Edgar Link	pending
FilingSummary.xml	Edgar Link	unprocessable
R12.htm	Edgar Link	pending
R13.htm	Edgar Link	pending
R14.htm	Edgar Link	pending
R15.htm	Edgar Link	pending
R16.htm	Edgar Link	pending
R17.htm	Edgar Link	pending
R18.htm	Edgar Link	pending
R19.htm	Edgar Link	pending
R2.htm	Edgar Link	pending
R20.htm	Edgar Link	pending
R21.htm	Edgar Link	pending
R22.htm	Edgar Link	pending
R23.htm	Edgar Link	pending
R24.htm	Edgar Link	pending
R25.htm	Edgar Link	pending
R26.htm	Edgar Link	pending
R27.htm	Edgar Link	pending
R28.htm	Edgar Link	pending
R29.htm	Edgar Link	pending
R3.htm	Edgar Link	pending
R30.htm	Edgar Link	pending
R31.htm	Edgar Link	pending
R32.htm	Edgar Link	pending
R33.htm	Edgar Link	pending
R34.htm	Edgar Link	pending
R35.htm	Edgar Link	pending
R36.htm	Edgar Link	pending
R37.htm	Edgar Link	pending
R38.htm	Edgar Link	pending
R39.htm	Edgar Link	pending
R4.htm	Edgar Link	pending
R40.htm	Edgar Link	pending
R41.htm	Edgar Link	pending
R42.htm	Edgar Link	pending
R43.htm	Edgar Link	pending
R44.htm	Edgar Link	pending
R45.htm	Edgar Link	pending
R46.htm	Edgar Link	pending
R47.htm	Edgar Link	pending
R48.htm	Edgar Link	pending
R49.htm	Edgar Link	pending
R5.htm	Edgar Link	pending
R50.htm	Edgar Link	pending
R51.htm	Edgar Link	pending
R52.htm	Edgar Link	pending
R53.htm	Edgar Link	pending
R54.htm	Edgar Link	pending
R55.htm	Edgar Link	pending
R56.htm	Edgar Link	pending
R57.htm	Edgar Link	pending
R58.htm	Edgar Link	pending
R59.htm	Edgar Link	pending
R6.htm	Edgar Link	pending
R60.htm	Edgar Link	pending
R61.htm	Edgar Link	pending
R62.htm	Edgar Link	pending
R63.htm	Edgar Link	pending
R64.htm	Edgar Link	pending
R65.htm	Edgar Link	pending
R66.htm	Edgar Link	pending
R67.htm	Edgar Link	pending
R68.htm	Edgar Link	pending
R69.htm	Edgar Link	pending
R7.htm	Edgar Link	pending
R70.htm	Edgar Link	pending
R71.htm	Edgar Link	pending
R72.htm	Edgar Link	pending
R73.htm	Edgar Link	pending
R74.htm	Edgar Link	pending
R75.htm	Edgar Link	pending
R76.htm	Edgar Link	pending
R77.htm	Edgar Link	pending
R78.htm	Edgar Link	pending
R8.htm	Edgar Link	pending
R9.htm	Edgar Link	pending
report.css	Edgar Link	pending
Show.js	Edgar Link	pending
zyme-20221231.htm	Edgar Link	pending
zyme-20221231.xsd	Edgar Link	pending
zyme-20221231xex1059.htm	Edgar Link	pending
zyme-20221231xex1064.htm	Edgar Link	pending
zyme-20221231xex1074.htm	Edgar Link	pending
zyme-20221231xex211.htm	Edgar Link	pending
zyme-20221231xex231.htm	Edgar Link	pending
zyme-20221231xex311.htm	Edgar Link	pending
zyme-20221231xex312.htm	Edgar Link	pending
zyme-20221231xex321.htm	Edgar Link	pending
zyme-20221231xex322.htm	Edgar Link	pending
zyme-20221231xex41.htm	Edgar Link	pending
zyme-20221231_g1.jpg	Edgar Link	pending
zyme-20221231_g2.jpg	Edgar Link	pending
zyme-20221231_g3.jpg	Edgar Link	pending
zyme-20221231_def.xml	Edgar Link	unprocessable
zyme-20221231_pre.xml	Edgar Link	unprocessable
zyme-20221231_lab.xml	Edgar Link	unprocessable
zyme-20221231_htm.xml	Edgar Link	completed
zyme-20221231_cal.xml	Edgar Link	unprocessable

Create your account

Find Stocks Worth Researching

Deeply Understand Businesses

Value Businesses Intelligently

$ZYME
Zymeworks Inc. Stock $zyme

2023 Q1 Form 10-K Financial Statement

#000193765323000011 Filed on March 07, 2023

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$ZYME Zymeworks Inc. Stock $zyme

2023 Q1 Form 10-K Financial Statement

#000193765323000011 Filed on March 07, 2023

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$ZYME
Zymeworks Inc. Stock $zyme